PRESS RELEASE published on 03/18/2025 at 18:00, 1 year 6 months ago Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC Oxurion NV receives transparency notifications from Atlas Special Opportunities, LLC regarding selling of voting securities, crossing thresholds. Developing ophthalmic therapies for retinal disease Atlas Special Opportunities Ophthalmic Therapies Oxurion NV Retinal Disease Transparency Notifications
BRIEF published on 03/04/2025 at 19:05, 1 year 6 months ago Oxurion Extends Financing Agreement With Atlas Convertible Bonds Market Capitalization Atlas Special Opportunities Oxurion Financing Program
PRESS RELEASE published on 03/04/2025 at 19:00, 1 year 6 months ago Oxurion Extends Its Financing Program Oxurion NV signs third amendment to convertible bond subscription agreement with Atlas Special Opportunities II, LLC, extending issuance period and clarifying maturity terms Amendment Convertible Bond Oxurion NV Atlas Special Opportunities II Financing Terms
BRIEF published on 02/14/2025 at 19:05, 1 year 7 months ago Oxurion Enhances Board with Nelly Souleymane's Appointment Innovation Board Changes Biopharmaceutical Diversity Oxurion
PRESS RELEASE published on 02/14/2025 at 19:00, 1 year 7 months ago Oxurion strengthens its Board of Directors with the arrival of Nelly Souleymane Oxurion NV announces changes in Board of Directors with the departure of two members and the integration of Nelly Souleymane, strengthening governance and strategic expertise in communication Board Of Directors Governance Communication Oxurion NV Nelly Souleymane
BRIEF published on 01/20/2025 at 18:05, 1 year 8 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Transparency Notification Share Acquisition Atlas Special Opportunities Oxurion Retinal Disease Therapies
PRESS RELEASE published on 01/20/2025 at 18:00, 1 year 8 months ago Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Oxurion NV receives transparency notification regarding shares ownership from Atlas Special Opportunities, LLC, crossing the 20% threshold. Company engaged in developing ophthalmic therapies Transparency Notification Ophthalmic Therapies Oxurion NV Shares Ownership Belgian Transparency Legislation
BRIEF published on 01/14/2025 at 18:05, 1 year 8 months ago Oxurion Receives Transparency Update from Atlas Special Opportunities LLC Actions Transparency Atlas Biopharmaceutical Oxurion
PRESS RELEASE published on 01/14/2025 at 18:00, 1 year 8 months ago Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities LLC Oxurion NV announces receiving an amended transparency notification regarding share ownership by Atlas Special Opportunities, LLC, crossing under the 3% threshold Transparency Notification Share Ownership Atlas Special Opportunities LLC Oxurion NV Retinal Disease
BRIEF published on 01/13/2025 at 18:05, 1 year 8 months ago Oxurion Updates Voting Rights Following Convertible Bond Conversion Voting Rights Convertible Bonds Capital Increase Market Opportunities Oxurion
Published on 10/03/2026 at 02:35, 19 hours 6 minutes ago Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 13:50, 1 day 7 hours ago AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 8 hours ago Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 8 hours ago Alaska Energy Metals Appoints Independent Director, Thomas Benson
Published on 10/03/2026 at 15:45, 5 hours 56 minutes ago Huawei Highlights Continuous Innovation, Securing Competitive Edge Through Technological Breakthroughs
Published on 10/02/2026 at 23:55, 21 hours 46 minutes ago IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 1 day 1 hour ago EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 1 day 1 hour ago innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 18:00, 1 day 3 hours ago EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 17:45, 1 day 3 hours ago Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/01/2026 at 19:00, 2 days 2 hours ago AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 2 days 3 hours ago Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 2 days 3 hours ago Covivio - Information on total number of voting rights and share capital
